阿尔茨海默病的流行病学。
Epidemiology of Alzheimer disease.
机构信息
Gertrude H. Sergievsky Center, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Medical Center, New York, NY 10032, USA.
出版信息
Cold Spring Harb Perspect Med. 2012 Aug 1;2(8):a006239. doi: 10.1101/cshperspect.a006239.
Abstract
The global prevalence of dementia has been estimated to be as high as 24 million, and is predicted to double every 20 years until at least 2040. As the population worldwide continues to age, the number of individuals at risk will also increase, particularly among the very old. Alzheimer disease is the leading cause of dementia beginning with impaired memory. The neuropathological hallmarks of Alzheimer disease include diffuse and neuritic extracellular amyloid plaques in brain that are frequently surrounded by dystrophic neurites and intraneuronal neurofibrillary tangles. The etiology of Alzheimer disease remains unclear, but it is likely to be the result of both genetic and environmental factors. In this review we discuss the prevalence and incidence rates, the established environmental risk factors, and the protective factors, and briefly review genetic variants predisposing to disease.
摘要
全球痴呆症的患病率估计高达 2400 万，预计至少到 2040 年每 20 年翻一番。随着全球人口老龄化，患病风险人群也会增加，尤其是非常高龄人群。阿尔茨海默病是痴呆症的主要病因，从记忆障碍开始。阿尔茨海默病的神经病理学特征包括大脑中弥漫性和神经突状细胞外淀粉样斑块，这些斑块通常被萎缩的神经突和细胞内神经原纤维缠结所包围。阿尔茨海默病的病因尚不清楚，但可能是遗传和环境因素共同作用的结果。在这篇综述中，我们讨论了患病率和发病率、已确定的环境风险因素和保护因素，并简要回顾了导致疾病的遗传变异。
相似文献
1
Epidemiology of Alzheimer disease.阿尔茨海默病的流行病学。
Cold Spring Harb Perspect Med. 2012 Aug 1;2(8):a006239. doi: 10.1101/cshperspect.a006239.
2
Epidemiology of Alzheimer disease.阿尔茨海默病的流行病学。
Nat Rev Neurol. 2011 Mar;7(3):137-52. doi: 10.1038/nrneurol.2011.2. Epub 2011 Feb 8.
3
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers.阿尔茨海默病：流行病学、诊断标准、危险因素和生物标志物。
Biochem Pharmacol. 2014 Apr 15;88(4):640-51. doi: 10.1016/j.bcp.2013.12.024. Epub 2014 Jan 4.
4
Increased risk of type 2 diabetes in Alzheimer disease.阿尔茨海默病患者患2型糖尿病的风险增加。
Diabetes. 2004 Feb;53(2):474-81. doi: 10.2337/diabetes.53.2.474.
5
[Vascular risk factors in demented elderly: analysis of Alzheimer Clinic materials].[老年痴呆患者的血管危险因素：阿尔茨海默病诊所资料分析]
Neurol Neurochir Pol. 2001 Mar-Apr;35(3):405-13.
6
Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?2型糖尿病患者患阿尔茨海默病的风险增加：是大脑胰岛素抵抗还是胰岛素诱导的淀粉样蛋白病变？
Biochem Soc Trans. 2005 Nov;33(Pt 5):1041-4. doi: 10.1042/BST0331041.
7
Aggregation of vascular risk factors and risk of incident Alzheimer disease.血管危险因素聚集与阿尔茨海默病发病风险
Neurology. 2005 Aug 23;65(4):545-51. doi: 10.1212/01.wnl.0000172914.08967.dc.
8
The epidemiology of the dementias: an update.痴呆症的流行病学：最新进展。
Curr Opin Psychiatry. 2007 Jul;20(4):380-5. doi: 10.1097/YCO.0b013e32816ebc7b.
9
Progression of Alzheimer-related neuritic plaque pathology in the entorhinal region, perirhinal cortex and hippocampal formation.内嗅区、嗅周皮质和海马结构中阿尔茨海默病相关神经炎性斑块病理的进展。
Dement Geriatr Cogn Disord. 1999 Mar-Apr;10(2):70-6. doi: 10.1159/000017104.
10
Atherosclerosis and AD: analysis of data from the US National Alzheimer's Coordinating Center.动脉粥样硬化与阿尔茨海默病：来自美国国家阿尔茨海默病协调中心的数据分析
Neurology. 2005 Feb 8;64(3):494-500. doi: 10.1212/01.WNL.0000150886.50187.30.
引用本文的文献
1
Bibliometric Analysis of the Epidemiological Research on Alzheimer's Disease Treatment.阿尔茨海默病治疗流行病学研究的文献计量分析
Cureus. 2025 Jul 7;17(7):e87484. doi: 10.7759/cureus.87484. eCollection 2025 Jul.
2
Burden and risk factors of Alzheimer's disease and other dementias in Vietnam from 1990 to 2021 - A comprehensive analysis from global burden disease.1990年至2021年越南阿尔茨海默病及其他痴呆症的负担和风险因素——来自全球疾病负担的综合分析
Cereb Circ Cogn Behav. 2025 Jun 30;9:100390. doi: 10.1016/j.cccb.2025.100390. eCollection 2025.
3
Demographic inaccuracies and biases in the depiction of patients by artificial intelligence text-to-image generators.人工智能文本到图像生成器在描绘患者时的人口统计学不准确和偏差。
NPJ Digit Med. 2025 Jul 19;8(1):459. doi: 10.1038/s41746-025-01817-6.
4
The Potential for Neuromodulation in the Treatment of Alzheimer's Disease: A Review of Clinical Trials.神经调节在阿尔茨海默病治疗中的潜力：临床试验综述
Cureus. 2025 May 31;17(5):e85156. doi: 10.7759/cureus.85156. eCollection 2025 May.
5
Cross-sectional and longitudinal Biomarker extraction and analysis for multicentre FLAIR brain MRI.多中心液体衰减反转恢复序列脑磁共振成像的横断面和纵向生物标志物提取与分析
Neuroimage Rep. 2022 Mar 8;2(2):100091. doi: 10.1016/j.ynirp.2022.100091. eCollection 2022 Jun.
6
Intracranial volume segmentation for neurodegenerative populations using multicentre FLAIR MRI.使用多中心液体衰减反转恢复磁共振成像（FLAIR MRI）对神经退行性疾病人群进行颅内体积分割
Neuroimage Rep. 2021 Mar 11;1(1):100006. doi: 10.1016/j.ynirp.2021.100006. eCollection 2021 Mar.
7
Diagnostic value of olfactory function testing for Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis.嗅觉功能测试对阿尔茨海默病和轻度认知障碍的诊断价值：一项系统评价和荟萃分析。
Front Aging Neurosci. 2025 May 15;17:1551939. doi: 10.3389/fnagi.2025.1551939. eCollection 2025.
8
Cerebrovascular Management Considerations in Patients on AATs.接受抗凝血酶治疗患者的脑血管管理考量
J Clin Med. 2025 May 14;14(10):3420. doi: 10.3390/jcm14103420.
9
Modeling Alzheimer's Disease: A Review of Gene-Modified and Induced Animal Models, Complex Cell Culture Models, and Computational Modeling.阿尔茨海默病建模：基因修饰和诱导动物模型、复杂细胞培养模型及计算建模综述
Brain Sci. 2025 May 5;15(5):486. doi: 10.3390/brainsci15050486.
10
Characterizing Treatment Non-responders and Responders in Completed Alzheimer's Disease Clinical Trials.在已完成的阿尔茨海默病临床试验中对治疗无反应者和有反应者进行特征分析。
AMIA Annu Symp Proc. 2025 May 22;2024:1176-1185. eCollection 2024.
本文引用的文献
1
The genetics of Alzheimer disease.阿尔茨海默病的遗传学。
Cold Spring Harb Perspect Med. 2012 Oct 1;2(10):a006296. doi: 10.1101/cshperspect.a006296.
2
Treatment strategies targeting amyloid β-protein.靶向淀粉样β蛋白的治疗策略。
Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006387. doi: 10.1101/cshperspect.a006387.
3
The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment.有症状的阿尔茨海默病和轻度认知障碍的临床问题。
Cold Spring Harb Perspect Med. 2012 May;2(5):a006148. doi: 10.1101/cshperspect.a006148.
4
The neuropsychological profile of Alzheimer disease.阿尔茨海默病的神经心理学特征。
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a006171. doi: 10.1101/cshperspect.a006171.
5
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.阿尔茨海默病的有症状和非淀粉样蛋白/tau 相关的药物治疗。
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006395. doi: 10.1101/cshperspect.a006395.
6
Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets.开发针对 tau、选定的激酶和相关神经元蛋白靶点的治疗方法。
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006437. doi: 10.1101/cshperspect.a006437.
7
Neuropathological alterations in Alzheimer disease.阿尔茨海默病的神经病理学改变。
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189. doi: 10.1101/cshperspect.a006189.
8
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.阿尔茨海默病所致痴呆的诊断：美国国家老龄化研究所-阿尔茨海默病协会工作组关于阿尔茨海默病诊断指南的建议。
Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.
9
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.MS4A4/MS4A6E、CD2AP、CD33 和 EPHA1 上的常见变异与晚发性阿尔茨海默病相关。
Nat Genet. 2011 May;43(5):436-41. doi: 10.1038/ng.801. Epub 2011 Apr 3.
10
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease.载脂蛋白 A7（ABCA7）、膜表面抗原 4A6A/4A4E（MS4A6A/MS4A4E）、EPH 受体 A1（EPHA1）、CD33 和 CD2 相关蛋白激酶 A（CD2AP）上的常见变异与阿尔茨海默病有关。
Nat Genet. 2011 May;43(5):429-35. doi: 10.1038/ng.803. Epub 2011 Apr 3.
Zotero 插件